<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We performed nonmyeloablative HSCT in 6 patients with a newly described genetic <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo> syndrome caused by mutations in GATA2-a disease characterized by nontuberculous <z:e sem="disease" ids="C0026918" disease_type="Disease or Syndrome" abbrv="">mycobacterial infection</z:e>, <z:mp ids='MP_0000223'>monocytopenia</z:mp>, B- and NK-cell deficiency, and the propensity to transform to <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>/<z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Two patients received peripheral blood stem cells (PBSCs) from matched-related donors, 2 received PBSCs from matched-unrelated donors, and 2 received stem cells from umbilical cord blood (UCB) donors </plain></SENT>
<SENT sid="2" pm="."><plain>Recipients of matched-related and -unrelated donors received fludarabine and 200 cGy of total body irradiation (TBI); UCB recipients received <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> in addition to fludarabine and TBI as conditioning </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients received tacrolimus and <z:chebi fb="0" ids="9168">sirolimus</z:chebi> posttransplantation </plain></SENT>
<SENT sid="4" pm="."><plain>Five patients were alive at a median follow-up of 17.4 months (range, 10-25) </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients achieved high levels of donor engraftment in the hematopoietic compartments that were deficient pretransplantation </plain></SENT>
<SENT sid="6" pm="."><plain>Adverse events consisted of delayed engraftment in the recipient of a single UCB, GVHD in 4 patients, and immune-mediated <z:hpo ids='HP_0001876'>pancytopenia</z:hpo> and <z:hpo ids='HP_0000100'>nephrotic syndrome</z:hpo> in the recipient of a double UCB transplantation </plain></SENT>
<SENT sid="7" pm="."><plain>Nonmyeloablative HSCT in GATA2 deficiency results in reconstitution of the severely deficient monocyte, B-cell, and NK-cell populations and reversal of the clinical phenotype </plain></SENT>
<SENT sid="8" pm="."><plain>Registered at www.clinicaltrials.gov as NCT00923364 </plain></SENT>
</text></document>